NASDAQ · OLMA
Olema Pharmaceuticals, Inc.
U.S. listed stock · USD15-minute delay
Find an instrument
- AppleAAPL · NASDAQResearch →
- MicrosoftMSFT · NASDAQResearch →
- NvidiaNVDA · NASDAQResearch →
- AmazonAMZN · NASDAQResearch →
- AlphabetGOOGL · NASDAQResearch →
- Meta PlatformsMETA · NASDAQResearch →
- TeslaTSLA · NASDAQResearch →
- JPMorgan ChaseJPM · NYSEResearch →
- ExxonMobilXOM · NYSEResearch →
- WalmartWMT · NASDAQResearch →
- S&P 500 IndexSPX · S&PResearch →
- Nasdaq 100 IndexNDX · NASDAQResearch →
- Dow Jones Industrial AverageDJI · Dow JonesResearch →
- Cboe Volatility IndexVIX · CboeResearch →
- U.S. Dollar IndexDXY · ICEResearch →
- VIX futuresVX1! · Cboe Futures ExchangeResearch →
- DAX futuresFDAX1! · EurexResearch →
- Euro Stoxx 50 futuresFESX1! · EurexResearch →
- E-mini S&P 500 futuresES1! · CMEResearch →
- E-mini Nasdaq 100 futuresNQ1! · CMEResearch →
- E-mini Dow futuresYM1! · CBOTResearch →
- E-mini Russell 2000 futuresRTY1! · CMEResearch →
- WTI crude oil futuresCL1! · NYMEXResearch →
- Natural gas futuresNG1! · NYMEXResearch →
- Gold futuresGC1! · COMEXResearch →
- Silver futuresSI1! · COMEXResearch →
- Euro FX futures6E1! · CMEResearch →
- Japanese yen futures6J1! · CMEResearch →
- BitcoinBTCUSD · BitstampResearch →
- EtherETHUSD · BitstampResearch →
- Research Any U.S. stock or ETF tickerResearch →
No matching names. Type a U.S. stock ticker (for example MU) to research it.
Loading price chart…
15-minute delay. Chart times and available timeframes are controlled by the provider.
Earnings
Earnings calendarEarnings announcement for OLMA: Nov 9, 2026
Olema Pharmaceuticals, Inc. Common Stock is estimated to report earnings on 11/09/2026. The upcoming earnings date is derived from an algorithm based on a company's historical reporting dates. Our vendor, Zacks Investment Research, might revise this date in the future, once the company announces the actual earnings date. According to Zacks Investment Research, based on 5 analysts' forecasts, the consensus EPS forecast for the quarter is $-0.6. The reported EPS for the same quarter last year was $-0.49.
| Fiscal quarter end | Consensus EPS forecast | High | Low | Estimates |
|---|---|---|---|---|
| Sep 2026 | $-0.60 | $-0.50 | $-0.65 | 5 |
| Dec 2026 | $-0.64 | $-0.52 | $-0.70 | 5 |
| Mar 2027 | $-0.62 | $-0.55 | $-0.72 | 3 |
| Jun 2027 | $-0.66 | $-0.61 | $-0.75 | 3 |
Source: Nasdaq, based on Zacks Investment Research consensus estimates. Dates marked as expected may change.
News
Zacks · RTTNews · Fintel · The Motley Fool- Zacks · Oct 19, 8:00 AM EDTThe Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema OncologyAstraZeneca, Roche, Puma Biotechnology and Olema Oncology offer breast cancer treatment opportunities, with drug sales growth, pipeline advances and clinical milestones shaping prospects.
- Zacks · Oct 16, 8:45 AM EDT4 Breast Cancer Stocks to Watch During Breast Cancer Awareness MonthAZN, RHHBY, PBYI and OLMA offer exposure to breast cancer drug sales growth, expanded treatment approvals and clinical milestones that could shape prospects.
- RTTNews · Aug 13, 7:17 AM EDTOlema Appoints Jason O'Byrne As CFO(RTTNews) – Olema Pharmaceuticals Inc. (OLMA), a clinical-stage biopharmaceutical company, on Thursday appointed Jason O'Byrne as Chief Financial Officer.
- Fintel · Mar 27, 11:42 AM EDTWolfe Research Initiates Coverage of Olema Pharmaceuticals (OLMA) with Peer Perform RecommendationFintel reports that on March 27, 2026, Wolfe Research initiated coverage of Olema Pharmaceuticals (NasdaqGS:OLMA) with a Peer Perform recommendation. Analyst Price Forecast Suggests 230.98% Upside
- The Motley Fool · Mar 22, 12:28 PM EDTOlema Stock Up 242%, but Does a $122 Million Position Suggest More Upside Potential?Paradigm Biocapital Advisor increased its stake in Olema Pharmaceuticals by 750,000 shares in Q4 2025.
- Zacks · Mar 18, 9:35 AM EDTOlema Pharmaceuticals (OLMA) Loses 33.4% in 4 Weeks, Here's Why a Trend Reversal May be Around the CornerOlema Pharmaceuticals (OLMA) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
- The Motley Fool · Mar 16, 7:02 PM EDTBiotech Stock Up Nearly 300% Draws $68.7 Million Bet as Breast Cancer Drug Targets 2027 LaunchCormorant Asset Management established a new stake in Olema Pharmaceuticals, purchasing 2,750,000 shares in the fourth quarter.
- BNK Invest · Mar 9, 3:24 PM EDTNotable Monday Option Activity: CRWD, OLMA, COFLooking at options trading activity among components of the Russell 3000 index, there is noteworthy activity today in CrowdStrike Holdings Inc (Symbol: CRWD), where a total volume of 31,258 contracts has been traded thus far today, a contract volume which is representative of ap
- BNK Invest · Mar 9, 12:33 PM EDTOlema Pharmaceuticals Becomes Oversold (OLMA)Legendary investor Warren Buffett advises to be fearful when others are greedy, and be greedy when others are fearful. One way we can try to measure the level of fear in a given stock is through a technical analysis indicator called the Relative Strength Index, or RSI, which me
- Fintel · Feb 11, 4:31 PM ESTStifel Initiates Coverage of Olema Pharmaceuticals (OLMA) with Buy RecommendationFintel reports that on February 11, 2026, Stifel initiated coverage of Olema Pharmaceuticals (NasdaqGS:OLMA) with a Buy recommendation. Analyst Price Forecast Suggests 99.02% Upside
- BNK Invest · Jan 30, 10:53 AM ESTOLMA May 15th Options Begin TradingInvestors in Olema Pharmaceuticals Inc (Symbol: OLMA) saw new options begin trading today, for the May 15th expiration. One of the key inputs that goes into the price an option buyer is willing to pay, is the time value, so with 105 days until expiration the newly trading contr
- BNK Invest · Jan 22, 3:21 PM ESTNoteworthy Thursday Option Activity: NVRI, OLMA, INSPAmong the underlying components of the Russell 3000 index, we saw noteworthy options trading volume today in Enviri Corp (Symbol: NVRI), where a total of 5,444 contracts have traded so far, representing approximately 544,400 underlying shares. That amounts to about 46.1% of NVR
Stories from Nasdaq.com, including Zacks, The Motley Fool and Barchart. They open on the publisher’s site; AiFs Market does not edit or endorse them.
Company profile
Loading company profile…
Financials
Loading fundamental data…
More headlines
More stories for Olema Pharmaceuticals, Inc. from TradingView. Coverage varies.
Loading related news…
Quotes, charts, company information and headlines are supplied by TradingView. Data may be delayed or unavailable. This page is for market research and does not provide investment advice.